This report uses market-leading social listening techniques and analytics to uncover the experiences,
frustrations and needs of Alzheimer’s patients and carers.
With increasing focus on disease modifying treatments in the Alzheimer’s space,
multiple touchpoints are highlighted where pharma can support and enhance the treatment
management process
for all stakeholders.
In August 2024, Ipsos' Alzheimer's Disease Consumer Study captured the perspectives of 800 participants to understand willingness to undergo blood biomarker testing for Alzheimer’s. Outputs provide critical insights to better understand consumer readiness for early detection - and early therapeutic intervention - as groundbreaking blood tests and imaging techniques become ever closer to approval.
A series of five reports that brings the MS patient voice directly to pharma. Conducted over two years, Ipsos’ MS Patient Community offered unique visibility of patients’ unmet needs via an ongoing online panel of those living with the condition. Interactive activities focused on specific elements of the MS patient journey, offering insights to support a patient-centric strategy.
Drawing from Ipsos' MS Therapy Monitor data, we analyse treatment patterns across the RRMS patient cohort over a 10-year period. We document the growing role of patient involvement, market dynamics following key patent expirations, and include a focus on the SPMS and PPMS therapeutic landscapes, as moves to treat these under-represented patient segments picks up pace.
The anti-CD20 monoclonal antibodies (mAbs) have become an integral part of the use of a high-efficacy treatment as 1st line therapy in active RRMS patients. By comparing insights from two distinct timepoints captured in Ipsos’ MS Therapy Monitor, this comprehensive report focuses on anti-CD20 usage trends in RRMS patients and their transformative impact on the overall treatment landscape.
With the advent of disease-modifying therapies (DMTs) that specifically work to slow disease progression in Alzheimer’s disease, biopharmaceutical stakeholders face a rapidly-shifting therapeutic environment. For companies navigating the US treatment market during this uniquely pivotal period, this report details the post-launch impact of new DMTs and how prescribing dynamics are unfolding in real-world practice.
This report offers unprecedented visibility into the minds of MS specialists to reveal core psychological drivers that influence disease modifying treatment (DMT) selection. Ipsos’ Brand Value Creator (BVC) measures the desire to use a particular therapy against constraints preventing its usage and quantifies their relative impact on market share, allowing you to understand how HCPs make choices and how to grow your brand.